Rigel Pharmaceuticals Inc
RIGLHealthcare|Biotechnology|USA
$42.55
-1.22 (-2.79%)
DCF (FCF)
$12.26
Tangible Book
$20.33
Graham Number
$92.54
Upcoming Data Readouts (11)
Aug 2026
Est. completion
P1P2Low Risk Myelodysplastic Syndromes
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264n=86
Apr 2027
Est. completion
P4AML (Acute Myeloid Leukemia)
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07486713n=16
Jun 2027
Est. completion
P2Targeted Therapy
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
NCT07032727n=68
Jun 2027
Est. completion
P1P2Mutant IDH1 Inhibitor Olutasidenib
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
NCT06445959n=78
Aug 2027
Est. completion
P2Myelodysplastic Syndromes
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
NCT06566742n=15
Dec 2027
Est. completion
P1Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
NCT06639724n=36
Jun 2028
Est. completion
P2IDH1 Mutation
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
NCT07471841n=25
Oct 2028
Est. completion
P1Acute Myeloid Leukemia
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
NCT07130695n=15
Jan 2029
Est. completion
P1Chronic Graft Versus Host Disease
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
NCT06233110n=30
Mar 2029
Est. completion
P2Acute Myeloid Leukemia
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
NCT06782542n=16
Jun 2029
Est. completion